Pharmaceutical company PSK Pharmaceuticals receives "Made in Russia" certificate from the Russian Export Center

October 23, 2026

PSK Pharma, headquartered in Moscow (a subsidiary of the Russian biopharmaceutical group), has received "Made in Russia" certification from the Russian Export Center (REC, VEB.RF) for approximately 100 pharmaceutical products. This certification, covering three aspects— reliability, quality, and uniqueness— highlights the company's significant export potential. PSK Pharma expects its pharmaceutical exports to increase by 60% by 2025 compared to 2024. By the end of 2026, the export growth rate is projected to reach approximately 69% compared to 2025.

This is partly due to the Russian Export Center's certification— the "Made in Russia" label provides international regulatory bodies, distributors, and the medical community with additional assurance of product quality and reliability. This strategic tool will help expedite the registration of pharmaceuticals in the Eurasian Economic Union and CIS countries and solidify the company's position in the international market.

“Today, Russian pharmaceutical companies are not only able to ensure national drug security, but also compete in the global high-tech field. The Russian Export Center has recognized our products in three areas, proving that our biotechnology drugs meet the highest international standards. The "Made in Russia" label will be a powerful tool for our further development: we plan to expand our business in the Eurasian Economic Union and CIS countries, and increase the supply of high-tech drugs to other countries. In this way, we are directly moving towards the goals of the ‘Pharmaceutical Strategy 2030’ and contributing to the growth of the country’s non-resource-based exports,” noted Evgenia Shapiro, CEO of PSK Pharma.

“The pharmaceutical industry is one of the most important sectors with huge export potential, and we are very pleased to welcome PSK Pharma to the ranks of companies certified by the Russian Export Center as "Made in Russia". We believe that with the issuance of the "Made in Russia" certification mark, the company will continue to successfully expand into new market areas with its national brand, as this mark guarantees product quality,” noted Alexander Morozov, Vice President of the Russian Export Center.

The core products receiving the "Made in Russia" certification are respiratory medications: approximately 30 products, including a range of inhaled medications for treating bronchial asthma and chronic obstructive pulmonary disease (COPD). According to the company, in Russia, almost one in two bronchial asthma patients uses medications from PSK Pharma.
A significant portion of the company's product portfolio focuses on orphan drugs, including those for pulmonary hypertension, idiopathic pulmonary fibrosis, Gaucher disease, phenylketonuria, hereditary angioedema, short bowel syndrome, and immune thrombocytopenic purpura.

The portfolio also includes drugs for autoimmune and neurological disorders, HIV antiretroviral therapy, and antiviral agents. Antifungal drugs and antibiotics for the treatment of severe and drug-resistant hospital-acquired infections, as well as cardiology, endocrinology, and obstetrics and gynecology drugs, have also been approved.

The company 's core therapeutic areas—modern inhaled medications for the treatment of bronchial asthma and chronic obstructive pulmonary disease—have the largest demand in overseas markets, accounting for over 90% of total exports. PSK Pharma's main markets are currently Belarus, Uzbekistan, and Azerbaijan.